Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Piper recommends that investors buy Achillion (NASDAQ:ACHN) on any weakness following its presentations of data at EASL, as the firm believes that data from Abbott Pharmaceuticals (NYSE:ABT) on its HCV treatment are impressive and validates Achillion’s potential future HCV treatment.The firm views Achillion as a likely takeover target and maintains an Overweight rating on the stock.
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX): Allscripts shares defended at Sterne Agee
Thoratec Corp. (NASDAQ:THOR): Thoratec recall likely same as voluntary recall in March, says Leerink
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.